Phase II Study Of Pirfenidone In Idiopathic Pulmonary Fibrosis Patients

InterMune, Inc (Nasdaq: ITMN) today announced that the American Journal of Respiratory andCritical Care Medicine (AJRCCM) published results from a double-blind,randomized, placebo-controlled Phase II trial evaluating pirfenidone for thetreatment of patients with idiopathic pulmonary fibrosis (IPF)... click link for more info.

Continue to Phase II Study Of Pirfenidone In Idiopathic Pulmonary Fibrosis Patients on Medical News Today.

Medical Buzz delivers the most recent headlines from the medical world. Diseases, cures, accidents, medicin. Click below for more headlines ...
Medical buzz